Pharmacokinetic modulator (PK modulator)

A pharmacokinetic modulator, also known as a pharmacokinetic enhancer or "booster," is a pharmacological agent used in combination therapy to optimize the absorption, distribution, metabolism, or excretion (ADME) profile of a primary therapeutic drug (NIH, 2023). These agents generally lack intrinsic therapeutic activity against the target disease at the doses administered; instead, they function by inhibiting biological barriers like the Cytochrome P450 3A4 (CYP3A4) enzyme or the P-glycoprotein (P-gp) transporter (FDA, 2014; PubChem, 2024). This inhibition effectively "boosts" the plasma concentration and extends the half-life of the co-administered drug, which is particularly critical in treating HIV and Hepatitis C to ensure consistent viral suppression and allow for less frequent dosing (StatPearls, 2023; DrugBank, 2024). Common examples include ritonavir and cobicistat, which are essential components of many antiretroviral regimens. However, because these modulators non-selectively inhibit metabolic pathways, they carry a high risk for clinically significant drug-drug interactions with other medications, requiring careful patient management and monitoring (PubMed, 2022).

Other names

Pharmacokinetic enhancerPharmacokinetic boosterPharmacoenhancerBooster agent

Pharmacokinetic modulators function by potently inhibiting specific drug-metabolizing enzymes, most notably Cytochrome P450 3A4 (CYP3A4), or drug efflux transporters like P-glycoprotein, to reduce the clearance and increase the systemic exposure of a co-administered therapeutic agent (NIH, 2023; FDA, 2014).